摘要: Neoadjuvant chemotherapy is frequently used for selected patients with operable breast cancer to reduce the tumor size and to facilitate breast conserving surgery. In patients with HER2-positive breast cancer, the neoadjuvant use of anthracycline-based chemotherapy in association with trastuzumab (concomitantly or sequentially) is well established following data from randomized studies but very few of them have reported long term follow-up.Buzdar et al (1-2) reported significantly higher pathologic complete response (pCR) rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy in comparison with paclitaxel and FEC alone (pCR of 65% versus 26% respectively, p= 0.016). DFS was significantly better among patients randomly allocated to chemotherapy plus trastuzumab compared with patients randomly allocated to chemotherapy alone (p= 0.04). The median follow-up was 36.1 …